About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a company based in Conshohocken (United States) founded in 2011 was acquired by Synta Pharmaceuticals in April 2016.. Madrigal Pharmaceuticals has raised $38.38 million across 2 funding rounds from investors including Madrigal. The company has 528 employees as of December 31, 2024. Madrigal Pharmaceuticals offers products and services including Rezdiffra. Madrigal Pharmaceuticals operates in a competitive market with competitors including NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Akero Therapeutics, among others.
- Headquarter Conshohocken, United States
- Employees 528 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Madrigal Pharmaceuticals, Inc.
-
Annual Revenue
$180.13 M0as on Dec 31, 2024
-
Net Profit
$-465.89 M-24.69as on Dec 31, 2024
-
EBITDA
$-496.78 M-30.74as on Dec 31, 2024
-
Total Equity Funding
$38.38 M (USD)
in 2 rounds
-
Latest Funding Round
$35 M (USD), Series A
Jun 30, 2017
- Investors
-
Employee Count
528
as on Dec 31, 2024
-
Acquired by
Synta Pharmaceuticals
(Apr 14, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol MDGL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Madrigal Pharmaceuticals
Madrigal Pharmaceuticals offers a comprehensive portfolio of products and services, including Rezdiffra. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats NASH with moderate to advanced liver fibrosis.
Unlock access to complete
Area Team
78 people
Leadership Team
68 people
Sales and Marketing
26 people
Operations Team
20 people
Thought Team
13 people
Data Analysis and Operations Team
12 people
Software Development Team
12 people
Product Management Team
11 people
Unlock access to complete
Funding Insights of Madrigal Pharmaceuticals
Madrigal Pharmaceuticals has successfully raised a total of $38.38M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $35 million completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $35.0M
-
First Round
First Round
(27 Apr 2016)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2017 | Amount | Series A - Madrigal Pharmaceuticals | Valuation |
investors |
|
| Apr, 2016 | Amount | Series A - Madrigal Pharmaceuticals | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Madrigal Pharmaceuticals
Madrigal Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Madrigal. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Small molecule drugs are developed for cancer and inflammatory diseases.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Madrigal Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Madrigal Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Madrigal Pharmaceuticals Comparisons
Competitors of Madrigal Pharmaceuticals
Madrigal Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Akero Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for metabolic disorders are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Madrigal Pharmaceuticals
Frequently Asked Questions about Madrigal Pharmaceuticals
When was Madrigal Pharmaceuticals founded?
Madrigal Pharmaceuticals was founded in 2011 and raised its 1st funding round 5 years after it was founded.
Where is Madrigal Pharmaceuticals located?
Madrigal Pharmaceuticals is headquartered in Conshohocken, United States. It is registered at Conshohocken, Pennsylvania, United States.
Is Madrigal Pharmaceuticals a funded company?
Madrigal Pharmaceuticals is a funded company, having raised a total of $38.38M across 2 funding rounds to date. The company's 1st funding round was a Series A of $3.38M, raised on Apr 27, 2016.
How many employees does Madrigal Pharmaceuticals have?
As of Dec 31, 2024, the latest employee count at Madrigal Pharmaceuticals is 528.
What is the annual revenue of Madrigal Pharmaceuticals?
Annual revenue of Madrigal Pharmaceuticals is $180.13M as on Dec 31, 2024.
What does Madrigal Pharmaceuticals do?
Madrigal Pharmaceuticals was founded in 2011 and is headquartered in Conshohocken, United States. Operations are centered on the development of small molecule therapeutics targeting cardiovascular and metabolic diseases, including non-alcoholic steatohepatitis. The company focuses on advancing drug candidates through clinical stages within the biopharmaceutical sector, with activities spanning research, preclinical testing, and regulatory processes in the United States.
Who are the top competitors of Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Akero Therapeutics.
What products or services does Madrigal Pharmaceuticals offer?
Madrigal Pharmaceuticals offers Rezdiffra.
Is Madrigal Pharmaceuticals publicly traded?
Yes, Madrigal Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol MDGL.
Who are Madrigal Pharmaceuticals's investors?
Madrigal Pharmaceuticals has 1 investor. Key investors include Madrigal.
What is Madrigal Pharmaceuticals's ticker symbol?
The ticker symbol of Madrigal Pharmaceuticals is MDGL on NASDAQ.